Artelo Biosciences Files to Effect 1-for-3 Reverse Stock Split to Boost Share Price

summarizeSummary

Artelo Biosciences will implement a 1-for-3 reverse stock split effective March 10, 2026, reducing outstanding shares to approximately 708,258, in an effort to improve marketability and maintain Nasdaq listing compliance.

check_boxKey Events · Corporate Governance and Compliance · ARTL

• Reverse Stock Split Filed

  The company filed a Certificate of Change with the State of Nevada to effect a 1-for-3 reverse stock split of its common stock.

• Effective Date Set

  The reverse stock split will be effective as of 12:01 a.m. Eastern Time on March 10, 2026.

• Share Count Adjustment

  Outstanding common shares will be reduced from 2,124,772 to approximately 708,258. Authorized common shares will also be proportionally reduced from 500,000,000 to 166,666,667.

• Purpose for Split

  The split is being effected to improve the marketability and liquidity of the common stock, directly addressing the need to maintain Nasdaq listing compliance following a recent extension and going concern warning.

auto_awesomeAnalysis · ARTL · Life Sciences

Artelo Biosciences has officially filed a Certificate of Change to implement a 1-for-3 reverse stock split, effective March 10, 2026. This action, which follows the company's recent 10-K filing disclosing a going concern warning and a Nasdaq listing extension, is a direct measure to increase the per-share price and improve marketability and liquidity, likely to meet Nasdaq's minimum bid price requirement. While the reverse split addresses an immediate compliance risk and theoretically boosts the stock price, it does not resolve the underlying operational or financial challenges. Investors should view this as a defensive maneuver, often indicative of a company struggling to maintain its listing and financial viability, especially given its current trading near 52-week lows.